Spruce Biosciences Stock Analysis
SPRB Stock | USD 0.39 0.01 2.63% |
Spruce Biosciences is undervalued with Real Value of 0.74 and Target Price of 1.83. The main objective of Spruce Biosciences stock analysis is to determine its intrinsic value, which is an estimate of what Spruce Biosciences is worth, separate from its market price. There are two main types of Spruce Biosciences' stock analysis: fundamental analysis and technical analysis.
The Spruce Biosciences stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Spruce Biosciences' ongoing operational relationships across important fundamental and technical indicators.
Spruce |
- SPRB Spruce Biosciences
- Latest NeoGenomics Tops Q4 Earnings Estimates
- SPRB 0.39 0.01
- Low 0.36
- High 0.41
- Alpha -0.26
- Beta 0.21
- Return On Equity -0.58
- Return On Asset -0.3
- Operating Margin (15.63) %
- Current Valuation (40.99 M)
- Shares Outstanding 41.3 M
- Shares Owned By Insiders 11.57 %
- Shares Owned By Institutions 44.04 %
- Number Of Shares Shorted 447.29 K
- Price To Book 0.31 X
- Price To Sales 2.26 X
- Revenue 10.09 M
- Gross Profit (28.96 M)
- EBITDA (47.37 M)
- Net Income (47.92 M)
- Cash And Equivalents 93.3 M
- Cash Per Share 3.96 X
- Total Debt 4.61 M
- Debt To Equity 0.07 %
- Current Ratio 9.55 X
- Book Value Per Share 1.25 X
- Cash Flow From Operations (33.27 M)
- Short Ratio 1.34 X
- Earnings Per Share (0.95) X
- Target Price 1.83
- Number Of Employees 22
- Beta 2.37
- Market Capitalization 16.07 M
- Total Asset 103.95 M
- Retained Earnings (197.23 M)
- Working Capital 77.72 M
- Net Asset 103.95 M
- Accumulation Distribution 0.12
- Daily Balance Of Power 0.2
- Rate Of Daily Change 1.03
- Day Median Price 0.39
- Day Typical Price 0.39
- Market Facilitation Index 0.05
- Price Action Indicator 0.01
- Period Momentum Indicator 0.01
Spruce Stock Analysis Notes
About 44.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.31. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Spruce Biosciences recorded a loss per share of 0.95. The entity had not issued any dividends in recent years. Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California. Spruce Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 17 people. To find out more about Spruce Biosciences contact MPH MD at 415 655 4168 or learn more at https://www.sprucebiosciences.com.Spruce Biosciences Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Spruce Biosciences' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Spruce Biosciences or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Spruce Biosciences generated a negative expected return over the last 90 days | |
Spruce Biosciences has some characteristics of a very speculative penny stock | |
Spruce Biosciences has high historical volatility and very poor performance | |
Spruce Biosciences has a very high chance of going through financial distress in the upcoming years | |
The company reported the previous year's revenue of 10.09 M. Net Loss for the year was (47.92 M) with loss before overhead, payroll, taxes, and interest of (28.96 M). | |
Spruce Biosciences currently holds about 93.3 M in cash with (33.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Spruce Biosciences has a frail financial position based on the latest SEC disclosures | |
Latest headline from zacks.com: NeoGenomics Tops Q4 Earnings Estimates |
Spruce Biosciences Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Spruce Biosciences previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
21st of March 2024 Upcoming Quarterly Report | View | |
20th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
21st of March 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Spruce Largest EPS Surprises
Earnings surprises can significantly impact Spruce Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2024-11-11 | 2024-09-30 | -0.24 | -0.21 | 0.03 | 12 | ||
2023-05-15 | 2023-03-31 | -0.36 | -0.4 | -0.04 | 11 | ||
2023-11-13 | 2023-09-30 | -0.35 | -0.3 | 0.05 | 14 |
Spruce Stock Institutional Investors
Shares | |||
Ubs Group Ag | 2024-12-31 | 86 K | |
Northern Trust Corp | 2024-12-31 | 80.3 K | |
Lion Point Capital, Lp | 2024-12-31 | 75 K | |
State Street Corp | 2024-12-31 | 60.7 K | |
Susquehanna International Group, Llp | 2024-12-31 | 59 K | |
Shay Capital Llc | 2024-12-31 | 38.1 K | |
Hrt Financial Llc | 2024-12-31 | 37.8 K | |
Xtx Topco Ltd | 2024-12-31 | 35.5 K | |
Bridgeway Capital Management, Llc | 2024-12-31 | 34.9 K | |
Rivervest Venture Management Llc | 2024-09-30 | 2.9 M | |
The Carlyle Group Inc | 2024-12-31 | 2.9 M |
Spruce Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 16.07 M.Spruce Profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.41) | (0.44) | |
Return On Capital Employed | (0.59) | (0.62) | |
Return On Assets | (0.41) | (0.44) | |
Return On Equity | (0.72) | (0.68) |
Management Efficiency
Spruce Biosciences has return on total asset (ROA) of (0.3035) % which means that it has lost $0.3035 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5755) %, meaning that it created substantial loss on money invested by shareholders. Spruce Biosciences' management efficiency ratios could be used to measure how well Spruce Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of March 3, 2025, Return On Tangible Assets is expected to decline to -0.44. In addition to that, Return On Capital Employed is expected to decline to -0.62. The current year's Other Current Assets is expected to grow to about 7.1 M, whereas Total Assets are forecasted to decline to about 89.5 M.Last Reported | Projected for Next Year | ||
Book Value Per Share | 1.79 | 1.48 | |
Tangible Book Value Per Share | 1.79 | 1.48 | |
Enterprise Value Over EBITDA | (0.40) | (0.42) | |
Price Book Value Ratio | 1.33 | 1.39 | |
Enterprise Value Multiple | (0.40) | (0.42) | |
Price Fair Value | 1.33 | 1.39 | |
Enterprise Value | 24.3 M | 23.1 M |
The strategic initiatives led by Spruce Biosciences' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Technical Drivers
As of the 3rd of March, Spruce Biosciences has the Coefficient Of Variation of (1,646), risk adjusted performance of (0.04), and Variance of 17.51. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Spruce Biosciences, as well as the relationship between them.Spruce Biosciences Price Movement Analysis
The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Spruce Biosciences middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Spruce Biosciences. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Spruce Biosciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Spruce Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Spruce Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Spruce Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Spruce Biosciences Outstanding Bonds
Spruce Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Spruce Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Spruce bonds can be classified according to their maturity, which is the date when Spruce Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Dana 575 percent Corp BondUS235822AB96 | View | |
SPIRIT AEROSYSTEMS INC Corp BondUS85205TAG58 | View | |
SPR 9375 30 NOV 29 Corp BondUS85205TAN00 | View | |
SPIRIT AEROSYSTEMS INC Corp BondUS85205TAK60 | View | |
SPRINT P 7625 Corp BondUS85207UAK16 | View | |
MPLX LP 4125 Corp BondUS55336VAK61 | View | |
MPLX LP 52 Corp BondUS55336VAL45 | View | |
SPRINT NEXTEL P Corp BondUS85208NAE04 | View |
Spruce Biosciences Predictive Daily Indicators
Spruce Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Spruce Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Spruce Biosciences Forecast Models
Spruce Biosciences' time-series forecasting models are one of many Spruce Biosciences' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Spruce Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Spruce Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Spruce Biosciences prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Spruce shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Spruce Biosciences. By using and applying Spruce Stock analysis, traders can create a robust methodology for identifying Spruce entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (4.27) | (4.49) | |
Operating Profit Margin | (4.64) | (4.87) | |
Net Loss | (4.27) | (4.49) | |
Gross Profit Margin | (3.51) | (3.69) |
Current Spruce Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Spruce analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Spruce analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
1.83 | Hold | 5 | Odds |
Most Spruce analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Spruce stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Spruce Biosciences, talking to its executives and customers, or listening to Spruce conference calls.
Spruce Stock Analysis Indicators
Spruce Biosciences stock analysis indicators help investors evaluate how Spruce Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Spruce Biosciences shares will generate the highest return on investment. By understating and applying Spruce Biosciences stock analysis, traders can identify Spruce Biosciences position entry and exit signals to maximize returns.
Begin Period Cash Flow | 24.7 M | |
Long Term Debt | 1.7 M | |
Common Stock Shares Outstanding | 38.5 M | |
Total Stockholder Equity | 76.5 M | |
Property Plant And Equipment Net | 1.2 M | |
Cash And Short Term Investments | 96.3 M | |
Cash | 96.3 M | |
Accounts Payable | 3.3 M | |
Net Debt | -91.7 M | |
50 Day M A | 0.3942 | |
Total Current Liabilities | 24.5 M | |
Other Operating Expenses | 62.1 M | |
Non Current Assets Total | 1.8 M | |
Non Currrent Assets Other | 582 K | |
Stock Based Compensation | 4.6 M |
Complementary Tools for Spruce Stock analysis
When running Spruce Biosciences' price analysis, check to measure Spruce Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Spruce Biosciences is operating at the current time. Most of Spruce Biosciences' value examination focuses on studying past and present price action to predict the probability of Spruce Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Spruce Biosciences' price. Additionally, you may evaluate how the addition of Spruce Biosciences to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |